Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinsuke Iida

Showing results (111-120 of 328) with videos related to

Pageof 33
Sort By:
Leukemia|July 30, 2022
Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemiaJolynn Zu Lin Ong, Rui Yokomori, Regina Wan Ju Wong, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 23, 2015
[Transplant-Related Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Busulfan-Based Reduced-Intensity Conditioning - A Retrospective Analysis in a Single Institution]Takashi Yoshida, Shigeru Kusumoto, Arisa Masuda, et al.
International Journal of Cancer|January 21, 2006
Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factorsAtsushi Inagaki, Takashi Ishida, Toshihiko Ishii, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 20, 2016
Novel monitoring of hepatitis B reactivation based on ultra-high sensitive hepatitis B surface antigen assayNoboru Shinkai, Shigeru Kusumoto, Shuko Murakami, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|January 14, 2010
[Anti-CCR4 monoclonal antibody as a novel therapy for advanced mycosis fungoides and Sézary syndrome]Hiroki Yano, Takashi Ishida, Atsushi Inagaki, et al.
International Journal of Hematology|December 24, 2024
DREAMM-11, Part 2: Japanese phase I trial of belantamab mafodotin combination therapies in relapsed/refractory multiple myelomaKazutaka Sunami, Shinsuke Iida, Nobuhiro Tsukada, et al.
International Journal of Hematology|April 16, 2022
Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatmentKosei Matsue, Kazutaka Sunami, Morio Matsumoto, et al.
Plos One|May 9, 2018
Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myelomaTakashi Yoshida, Masaki Ri, Shiori Kinoshita, et al.
Cancer Science|June 29, 2016
Dose-escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myelomaShinsuke Iida, Daisuke Ogiya, Yasunobu Abe, et al.
International Journal of Hematology|October 31, 2019
Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myelomaIsamu Sugiura, Kenshi Suzuki, Masaki Ri, et al.
Pageof 33

Showing results (111-120 of 328) with videos related to

Sort By:
Pageof 33
Leukemia|July 30, 2022
Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemiaJolynn Zu Lin Ong, Rui Yokomori, Regina Wan Ju Wong, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 23, 2015
[Transplant-Related Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Busulfan-Based Reduced-Intensity Conditioning - A Retrospective Analysis in a Single Institution]Takashi Yoshida, Shigeru Kusumoto, Arisa Masuda, et al.
International Journal of Cancer|January 21, 2006
Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factorsAtsushi Inagaki, Takashi Ishida, Toshihiko Ishii, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 20, 2016
Novel monitoring of hepatitis B reactivation based on ultra-high sensitive hepatitis B surface antigen assayNoboru Shinkai, Shigeru Kusumoto, Shuko Murakami, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|January 14, 2010
[Anti-CCR4 monoclonal antibody as a novel therapy for advanced mycosis fungoides and Sézary syndrome]Hiroki Yano, Takashi Ishida, Atsushi Inagaki, et al.
International Journal of Hematology|December 24, 2024
DREAMM-11, Part 2: Japanese phase I trial of belantamab mafodotin combination therapies in relapsed/refractory multiple myelomaKazutaka Sunami, Shinsuke Iida, Nobuhiro Tsukada, et al.
International Journal of Hematology|April 16, 2022
Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatmentKosei Matsue, Kazutaka Sunami, Morio Matsumoto, et al.
Plos One|May 9, 2018
Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myelomaTakashi Yoshida, Masaki Ri, Shiori Kinoshita, et al.
Cancer Science|June 29, 2016
Dose-escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myelomaShinsuke Iida, Daisuke Ogiya, Yasunobu Abe, et al.
International Journal of Hematology|October 31, 2019
Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myelomaIsamu Sugiura, Kenshi Suzuki, Masaki Ri, et al.
Pageof 33